BRIEF-Transgene announces phase 2 trial with Bristol-Myers Squibb for 2nd line treatment of metastatic non-small cell lung cancer
December 07, 2016 at 12:18 PM EST
* Transgene: UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo (nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (nsclc)
